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Cytotoxic effect of dose and schedule on normal murine
hematopoietic progenitor cells following the administration
of 4'-deoxydoxorubicin
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Summary In an experimental setting, 4'-deoxydoxorubicin (4'-deoxy-DX) shows minimal cardiotoxicity as
well as the marked antitumoral activity shown by doxorubicin, its parent compound. In this experimental
study, the haematologic toxicity of the new anthracycline was investigated by haematopoietic precursor cell
(HPC) assays using in vivo (colony-forming units - spleen, CFUS) and in vitro (CFU,-culture) methods with
(C57B1 xC3H)F1 mice. Dose-survival curves and time response of HPC in situ following 4'-deoxy-DX
administration were determined. In the time-related experiments, the effects of a single dose, an intermittent
treatment (Days 0, 2, and 5) and a prolonged biweekly administration were studied. All dose-survival curves
were exponential, with statistically significant differences between the effects on the various cell classes. CFUC
appeared more sensitive than CFU,. In time-related experiments, 4'-deoxy-DX toxicity for HPC seemed to be
relatively mild. However, CFU, sensitivity was again high in comparison with other populations assayed. In
long-term administration, the 4-deoxy-DX effects on the haematopoietic system were also rather slight.
Modifications of the chemical structure of DX may
significantly alter antitumour activity and toxicity
of the molecule.
Research along these lines has produced some
interesting derivatives of DX that have increased
therapeutic indices and therefore could have a
future in clinical application (Bonfante et al., 1979).
Of particular interest are compounds derived from
modifications at position 4' of the anthracycline
ring. Among these, 4'-deoxy-DX in an experimental
setting has shown minimal or zero cardiotoxicity
while maintaining the marked antitumoral activity
of the parent compound (Casazza et al., 1980;
Giuliani & Kaplan, 1980; Casazza et al., 1982). In a
human tumour stem cell assay, 4'-deoxy-DX had
the greatest in vitro potency among 10
simultaneously tested anthracyclines (Salmon et al.,
1981). The cytotoxic effects of 4'-deoxy-DX have
been studied in mice on various experimental
tumours (L1210 leukaemia, P388 leukaemia, Gross
leukaemia, solid 180 sarcoma, MS2 tumour, and
early mammary carcinoma). The new drug was
generally 2-3 times as potent and about twice as
toxic as DX. However, its cardiac toxicity was
much lower than that of DX, or even totally absent
at low dosages. Since these data were very
encouraging we decided to evaluate the toxic effects
of 4'-deoxy-DX on the haematopoietic system,
which could be the main dose-limiting factor of the
new compound.
Accordingly we assayed the in situ dose and time
response of HPC in mice treated with single or
repeated doses of 4'-deoxy-DX. The general
approach to this investigation was similar to that
used in our previous studies on haematologic
toxicity of other anthracycline derivatives
(Muzzulini et al., 1981; Massa et al., 1982; Sobrero
et al., 1982).
Materials and methods
Mice
All experiments were performed on 2-3 month old
(C57B1 x C3H)F1 mice. Irradiation of recipient
mice was performed with a Theratron Junior cobalt
60 apparatus (0.8 Gymin-1; total dose delivered,
9Gy).
Drug
4'-deoxy-DX (laboratory code IMI 58 batch
2634/50), supplied by Farmitalia Carlo Erba
(Milan, Italy) in the form of a red powder, was
stored in the dark in a desiccator at 4°C and drug
solutions were freshly prepared immediately before
use. The synthesis, structure, biologic and
pharmacologic activities of the compound have
been reported in several publications (Arcamone et
al., 1976; Plumbridge & Brown, 1979; Casazza et
al., 1980; Giuliani & Kaplan, 1980; Arcamone,
1981; Giuliani et al., 1981).
For use, the drug was dissolved in saline solution
and injected into the tail vein.
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Experimental design
Experiment A: Dose-survival curves ofin vivo HPC
in mice treated with 4'-deoxy-DX. The aim of this
experiment was to assess the shape and the slope of
in vivo dose-survival curves of haematopoietic cells
and HPC, which allowed a comparison between the
drug sensitivities of the various populations. In a
preliminary study, the lethal effects of 4'deoxy-DX
were studied in mice given different single doses of
the drug. The animals were kept under observation
for 31 days. On the basis of the mortality data, an
LD50 of 3.02mgkg-1 body wt was calculated. In
mice treated with 1.53mgkg-1 body wt, the
survival was 100%, whereas none of the mice
treated with 4.25mgkg-1 body wt survived. The
dose range for experiment A was selected on the
basis of these data. Five groups of 5 normal mice
each received a single i.v. injection of 4'-deoxy-DX
at various dose levels, i.e., 1.52, 1.81, 2.15, 2.55,
3.02, 3.58, and 4.25mgkg-1 body wt.
Twenty-four hours after i.v. injection, VPRC,
total leukocyte count, and the number of
reticulocytes per 100 RBC in orbital sinus blood
were determined. The mice were then killed by
cervical dislocation, femurs were removed, and
bone marrow cellularity and HPC content were
determined (see below).
Experiment B: Time-survival curvesfor bone marrow
HPC in mice treated with 4'-deoxy-
DX. The aim of this recovery experiment was to
assess the effect of the drug on HPC as a function
of time. A single LD50 dose (3.02mgkg-1 body wt)
was given to a group of 100 normal mice. At days
1, 2, 3, 5, 7, 9, 11, 13, 15 and 17, 5 treated mice
were subjected to the same determinations as in
experiment A.
Experiment C: Time-survival curves for bone
marrow HPC in mice treated with repeated doses of
4'-deoxy-DX According to previous experiments
(Casazza et al., 1980), a schedule of intermittent
treatment (days 0, 2, and 5) with DX or some of its
analogues appeared useful to test antitumoral
activity of the drugs. Therefore, it seemed
worthwhile to check the HPC toxicity of 4'-deoxy-
DX related to a similar schedule and to follow it
with time. Accordingly, a group of 80 normal mice
were given, on days 0, 2, and 5, a single i.v. dose of
2.55mgkg-1 of 4'deoxy-DX. This dose was selected
because in experiment A it induced a severe but not
dramatic reduction in HPC. The treated mice were
subjected to the aforementioned determinations on
Days 2, 3, 5, 7, 9, 11, 13, 15 and 17.
Experiment D: Time-survival curves for bone
marrow HPC in mice during long-term
administration of 4'-deoxy-DX. A comparison of
cardiac toxicity of DX and of its derivatives during
long-term administration of the drugs to mice
(treatment schedule: two treatments per week for 5
weeks and a 2 week interval between the second
and third weeks of treatment) showed that at a
dose corresponding to one-fifth of the LD50 4'-
deoxy-DX was much less cardiotoxic than other
anthracyclines (Casazza et al., 1980). The treatment
schedule was as follows: two i.v. administrations
per week for 2 weeks, followed by a 2-week interval
and then two administrations per week for 3 weeks.
Two drug levels were selected: the lower was
0.77mgkg-1 body wt per day, which was almost
one-fourth of the LD50 and which, as a single dose,
would not cause any reduction in bone marrow
HPC 24h after administration. The higher one was
2.15mgkg-1 body wt per day, which as a single
dose showed significant general and haematologic
toxicity. A group of 50 mice received the lower
dose and a group of 100 mice the higher one. At
the end of weeks 1, 2, 3, 4, 5, 6, 7, 10, 13 and 17,
the determinations on peripheral blood and on
bone marrow reported for experiment A were
performed on 5 treated mice.
For each experimental group there was a control
group composed of an equal number of saline-
treated controls.
Haematological methods
Peripheral blood cell counts, bone marrow
collection, and preparation of single cell
suspensions were performed by the usual techniques
(Dacie & Lewis, 1975). HPC were assayed as CFU5
by the transplant method of Till & McCulloch
(1961) and as CFUC by the in vitro method of
Bradley and Metcalf (1966). Technical details have
been reported in previous publications (Massa et
al., 1982; Sobrero et al., 1982).
Statistical methods
To prevent possible day-to-day variations in the
assays, single data points obtained in treated mice
and in controls were determined on the same day.
In the figures, the contents of CFUS and CFUC per
femur were normalized to those found in saline-
treated controls. The linear regressions between
drug doses and survival fractions were fitted by the
least squares method, and linear regression
coefficients (r) and their significance were
calculated. On the dose-survival curves, D37s were
calculated on the basis of the equation y=a+bx
(Bliss, 1970). Comparison between curves obtained
in experiment A was performed by analysis of
variance (F variance ratio and its significance).
In experiments B, C, and D, the values of drug-
treated mice and of controls were compared by
Student's t-test.4'-DEOXYDOXORUBICIN AND HAEMATOPOIETIC PROGENITORS 649
Results
General toxicity
In experiments B and C, the spontaneous death
rate during the 17-day observation period after
treatment with a single 3.02mg dose or with three
2.55mgkg- 1 doses was -60%. Marked hair and
weight loss was evident in the survivors. In
experiment D, the death rate in mice treated with
doses of 0.77mgkg-1 was negligible, whereas in
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mice treated with 2.15mgkg-1 doses it was -50%.
Hair and weight loss were evident in the survivors
only in the first 8 weeks of the experiment.
Experiment A: Dose-survival curves of peripheral
blood cells, bone marrow cells, bone marrow CFUS
and CFUC 24h after a single iniection of 4'-deoxy-
DX. Results are reported in Figures 1 and 2. The
legends include the regression coefficient of each
dose-survival curve and its significance. Within the
Retics
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Figure 1 Dose-survival curves of peripheral blood cells 24h after a single injection of 4'-deoxy-DX. For each
experimental point: vertical bars, means + s.e. The r's: WBC r= -0.97 (P<0.01); reticulocytes r= -0.98
(P<0.01).
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Figure 2 Dose-survival curves ofbone marrow cellularity and HPC 24h after a single injection of4'-deoxy-DX.
For each experimental point: vertical bars, means + s.e. The r's: CFUsr= -0.97 (P<0.0l); CFU,r= -0.99
(P<0.0l); bone marrowcellularity r = -0.99 (P<0.0l). The suspension ofbone marrow ofmice werepooled, and
a cell count was made on the pool, thus preventing statistical evaluation of bone marrow cellularity differences.
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Table I Comparison by analysis of variance between the
slopes of dose-survival curves of assayed populations 24
hours after a single injection of4'-deoxy-DX
CFU, vs b.m. cell (P<0.05) CFUC vs b.m.cell (P<0.01)
CFUS vs w.b.c. (P<0.05) CFUC vs w.b.c. (P<0.01)
CFUS vs retics NS CFUC vs retics (P<0.0l)
CFUS vs CFUC (P<0.01)
dose range used, all dose-survival curves were
exponential. By analysis of variance, the slopes of
dose-survival curves for each population assayed
were compared with one another. Results are
reported in Table I.
The D37s calculated in mgkg- 1 body wt for each
curve were as follows: reticulocytes, 2.96; WBC, 4;
bone marrow cellularity, 4.38; CFUC, 2.43; CFUS,
3.04. Bone marrow CFUC sensitivity to 4'-deoxy-
DX was the highest and that of CFUS lower.
Sensitivity of the two HPC populations assayed was
higher than that of bone marrow cells and of
peripheral WBC.
Experiment B: Time-survival curves of peripheral
blood cells and ofbone marrow cellularity, CFUs and
CFUC after a single 3.02mgkg-1 body wt dose of4'-
deoxy-DX. Results and their statistical significance
are reported in Figures 3 and 4. A single
administration of 3.02mgkg-' body wt did not
seem to affect the VPRC (not shown in Figures),
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but induced a rather modest reduction in peripheral
WBC and bone marrow cellularity which recovered,
however, within 5-7 days. This dose also caused a
more pronounced decrease in peripheral blood
reticulocytes, whose level remained below the
normal value for 15 days. Bone marrow CFU,
content significantly decreased to -40% of the
normal value and recovered to the control value by
day 7. The decrease in bone marrow CFUC was
more dramatic (nadir=5% of normal). This
population partially recovered by day 7 but did not
reach normal values for the rest of the experiment.
On the whole, the haematopoietic system showed
a good recovery capacity, which assured a return to
normal within 7-15 days. The only exception was
represented by the progenitor cells committed to
myeloid differentiation, which were the most
damaged and had a defective recovery. Moreover,
they showed a secondary decrease, which occurred
long after exposure to the drug.
Experiment C: Time-survival curves of peripheral
blood cells and ofbone marrow cellularity, CFUS and
CFUC during and after three repeated administrations
of 2.55 mg of 4'-deoxy-DX. Results and their
statistical significance are reported in Figures 5 and
6. The VPRC (not shown in Figures), was not
affected; the reticulocyte level was decreased by half
on day 3 and had returned to normal by day 7.
Most noteworthy was the progressive decline up to
days 5-7 of bone marrow cellularity, which showed
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Figure 3 Fractional survival of peripheral blood cells as a function of time after a single dose of 4'-deoxy-
DX. For each experimental point: vertical bars, means+s.e. Values marked with an asterisk are significantly
different (P<0.05) from those found in untreated mice. b.w.=body wt.
odg-- -4-
-71 i
*4'-DEOXYDOXORUBICIN AND HAEMATOPOIETIC PROGENITORS
b.m. cell
*+ * * CFU 8/+ + -- - T
* ** ~~~~~~~CFUs
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
1
4'-deoxyDoxorubicin 3.02 mg kg-1 b.w.
Time (d)
Figure 4 Fractional survival of bone marrow HPC and bone marrow cellularity as a function of time after a
single dose of 4'-deoxy-DX. For each experimental point: vertical bars, means + s.e. Values marked with an
asterisk are significantly different (P<0.05) from those found in treated mice. b.w. =body wt. The suspension
of bone marrow of mice were pooled, and a cell count was made on the pool, thus preventing statistical
evaluation of bone marrow cellularity differences.
a very marked decrease (to 4%), and of CFUS and
CFUC, which fell to <30%. Whereas bone marrow
cellularity and bone marrow CFU, content
eventually recovered, reaching normal or near
normal values by days 11-13, the CFUC recovery
appeared slow and did not reach normal values. In
the last 5 days of the observation period, there was
a marked secondary decline in bone marrow
cellularity levels, which at the end of the experiment
were still around the low value of 20%.
Overall, this schedule of administration of 4'-
deoxy-DX appeared to have a greater effect on the
bone marrow cells and HPC than on the peripheral
blood cells. In comparison with the single dose
administration, it delayed recovery for another 5-7
days. Also in this experiment the behaviour of
CFUC was peculiar in that it showed a relatively
inefficient recovery and a secondary decline. As in
experiment B, the decline occurred too late for it to
be caused by a direct toxic effect of the drug.
Experiment D: Time-survival curves of peripheral
blood cells and ofbone marrow cellularity, CFUS and
CFUC during and after prolonged treatment with 4'-
deoxy-DX. As can be seen from Figures 7 and 8,
repeated administration of 0.77mgkg- of 4'-
deoxy-DX had no effect on VPRC (not shown in
Figures), reticulocyte level, or bone marrow CFU
content of treated mice. Bone marrow cellularity
showed a modest decline during the first 2 weeks of
treatment, fully recovered during the 2-week
interval, and thereafter remained at normal levels.
WBC level and bone marrow CFUC content were
more susceptible to the toxic effect of the drug, and
showed a progressive decline until week 7.
Thereafter, there was a slow recovery; WBC
returned to normal values at the end of the
experimental period, whereas CFUC level remained
markedly low. In mice treated with a much more
toxic dose of the drug for several weeks, the VPRC
was not affected, whereas reticulocytes, WBC, and
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Figure 5 Fractional survival of peripheral blood cells as a function of time during and after an intermittent
schedule with 4'deoxy-DX. For each experimental point: vertical bars, means + s.e. Values marked with an
asterisk are significantly different (P<0.05) from the corresponding values of controls.
bone marrow CFUC declined during the treatment
period and thereafter recovered slowly, reaching
normal values at week 17 (WBC) or remaining at a
level well below normal (CFUC). Bone marrow
cellularity dropped during the first 2 weeks of
treatment, increased during the free interval, and
then slowly recovered. There was a slight, slow
decrease in bone marrow CFUS content for 6 weeks
and then a steady slow recovery to the normal
level. With this schedule of prolonged treatment, 4'-
deoxy-DX did not appear to be particularly toxic
for the haematopoietic system at a low dosage and
only mildly toxic at the higher one. The
haematopoietic system was able to fully recover
after 5 weeks of exposure to the drug. The main
toxic effect of 4'-deoxy-DX appeared to be on the
granulopoietic lineage.
Discussion
To evaluate the myelotoxic activity of a drug, the
assay of haematopoietic progenitor cell populations
appears to be a very valuable test (Marsh, 1976;
Lohrmann & Schreml, 1982). As can be seen from
previous research (Pannacciulli et al., 1982; Sobrero
et al., 1982), although there are no great differences
between the effects of different antitumoral drugs
on peripheral blood cells and bone marrow
cellularity, the differences may become evident
when HPC are evaluated.
Simple negative exponential dose-exposure curves
were obtained by assaying the in vivo effect of 4'-
deoxy-DX on bone marrow progenitor cells of mice
24h after administration of the drug. They showed
that 4'-deoxy-DX causes a dose-related reduction in
bone marrow HPC, and that it acts on all phases of
the cell cycle. An important feature of the curve is
the existence of a "shoulder" portion, i.e. the early
nonexponential tract, which is probably an
expression of the capacity of HPC to repair damage
induced by low doses of the drug. These results are
similar in pattern to those reported for other
anthracyclines (Razek et al., 1972; Alberts & Van
Daalen, 1976; Blackett et al., 1978; Buick et al.,
1979; Huybrechts et al., 1979; Marsh, 1979;
Muzzulini et al., 1981; Massa et al., 1982; Sobrero
et al., 1982).
There are some statistically significant differences
between the effects of the new anthracycline on the
various cell classes assayed. Progenitor cells
committed to myeloid differentiation (CFUC), which2.00-
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Figure 6 Fractional survival of bone marrow HPC and bone marrow cellularity as a function of time during
and after an intermittent schedule with 4'-deoxy-DX. For each experimental point: vertical bars, means + s.e.
Values marked with an asterisk are significantly different (P<0.05) from the corresponding values of controls.
The suspension of bone marrows of mice were pooled, and a cell count was made on the pool, thus
preventing statistical evaluation of bone marrow cellularity differences.
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Figure 7 Fractional survival of peripheral blood cells as a function of time during and after biweekly
treatment with 4'-deoxy-DX. For each experimental point: vertical bars, means + s.e. Values marked with an
asterisk are significantly different (P<0.05) from the corresponding values ofcontrols.
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in the normal steady state are much more
proliferative than pluripotent stem cells (CFUS)
(Lajtha, 1975), appear to be more sensitive to the
toxic effect of the drug than the latter. However,
the difference between CFUS and CFUC sensitivity
to 4'-deoxy-DX, while statistically significant, is not
proportional to the difference in kinetics between
the two populations. It is possible that, if there are
any differences caused by kinetics, these could be
masked by other factors that could be responsible
for an increase in CFUS or a decrease in CFUC
sensitivity. The higher CFUC sensitivity to the new
anthracycline derivative is also evident in time-
related experiments in which the bone marrow
CFUC level falls more dramatically than that of
other populations assayed. The CFUC recovery is
usually slower and still incomplete at the end of
experiments. Their secondary decline, which is
evident at the end of experiments B and C, cannot
be a result of the direct toxic effect of the drug,
since it occurs too long after drug exposure. A
similar trend of CFUC has been observed after three
injections of cytosine arabinoside (Page et al.,
1983).
However, in an experiment with 4'-epi-DX with a
longer observation time, the secondary decline was
eventually followed by a return to normal (Sobrero
et al., 1982). One may speculate that this is related
to the derangement of feedback mechanisms that
control population size, which may occur in the
case of depletion of bone marrow reserves.
Dose-response curves similar to those here
reported for 4'-deoxy-DX may be obtained by
plotting equal fractions and multiples of the LD50
of DX, 4'-epi-DX and 4'-demethoxydaunorubicin
against their effects on mice bone marrow HPC
(Massa et al., 1982; Sobrero et al., 1982). In
comparison with the parent drug DX, at an
equitoxic dose (LD50), both drugs exert a similar
toxic effect on bone marrow cellularity and on4'-DEOXYDOXORUBICIN AND HAEMATOPOIETIC PROGENITORS 655
peripheral blood cells. However, the reduction in
CFU5 and CFUC is higher in DX-treated than in 4'-
deoxy-DX-treated mice (respectively 20% survival
versus 40%, and 16% versus 24%). Thus the new
derivative, which is three times more potent than
DX as far as antitumoral activity and general and
haematologic toxicity are concerned, seems to have
a rather low toxicity for HPC. From this point of
view, its therapeutic index is better than that of the
parent drug, although not as good as the
therapeutic index concerning cardiotoxicity
(Casazza et al., 1980).
In time-survival experiments, the haematopoietic
system shows fair resilience to the toxic effect of 4'-
deoxy-DX. Following a single highly toxic dose of
the drug or repeated administration of smaller
doses, the pattern differs mainly as regards the
decline and recovery times. However, in both cases
recovery is complete except for the aforementioned
secondary reduction in CFUC. Considering that in
both experiments the dose injected was conspicuous
from the point of view of general toxicity,
haematologic toxicity and toxicity for HPC in
particular seem to be relatively mild compared to
the effect of other anthracyclines in similar
experimental conditions.
The administration of a small dose of the drug
for several weeks once more brings to light the
higher sensitivity of CFUC, because this population
together with its derivative, WBC, is the only one
depleted. Pluripotent stem cells appear completely
spared. With a much higher dose, bone marrow
cells and progenitors and peripheral blood cells are
all affected to different degrees. On the whole, 4'-
deoxy-DX appears to be a promising drug also
from the point of view of haematologic toxicity. At
doses that have the same antitumoral activity, 4'-
deoxy-DX appears less toxic or no more toxic than
DX. Therefore, its lower cardiotoxicity seems to be
fully exploitable. In repeated and long-term
administration, its toxic effect on HPC seems to be
rather slight.
Further research is needed to ascertain whether
this finding means that the new drug causes less
residual haematopoietic damage.
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